Free Trial
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel
NASDAQ:IVVD

Invivyd Q2 2025 Earnings Results & Report

Invivyd logo
$0.65 -0.03 (-4.05%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$0.65 +0.01 (+1.08%)
As of 07:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Invivyd missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.12 versus the -$0.04 consensus estimate, while revenue of $11.79 million fell short of the $23.16 million estimate by $11.38 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Invivyd EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Invivyd Revenue Results

Actual Revenue
$11.79 million
Expected Revenue
$23.16 million
Beat/Miss
Missed by -$11.38 million
YoY Revenue Growth
N/A

Upcoming Earnings

Invivyd's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q3 2026 Earnings Report

Conference Call Resources

Slide Deck

Invivyd's Q2 2025 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

Invivyd's Q2 2025 Press ReleasePress Release
(8-K)
Invivyd's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Invivyd Q2 2025 Earnings FAQ

Invivyd (NASDAQ:IVVD) reported earnings of -$0.12 per share for Q2 2025, missing the consensus estimate of -$0.04. The report was announced on Thursday, August 14, 2025.

Invivyd reported revenue of $11.79 million for Q2 2025, against a consensus estimate of $23.16 million.

Invivyd's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Invivyd on the company's earnings history page.

Invivyd Earnings Headlines

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380605/0/en/invivyd-and-the-spear-study-group-announce-initiation-of-flintlock-phase-2-study-of-vyd2311-a-monoclonal-antibody-for-the-potential-treatment-of-long-covid-or-post-vaccination-synd.html
IVVD Share News Today
October 12 at 5:47 PM  |  uk.investing.comhttps://uk.investing.com/equities/adagio-therapeutics-news
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
Arcus Biosciences (NYSE:RCUS) versus Invivyd (NASDAQ:IVVD) Head to Head Review
October 12 at 8:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110350
BTIG Sticks to Its Buy Rating for Invivyd (IVVD)
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IVVD/pressreleases/4900082/btig-sticks-to-its-buy-rating-for-invivyd-ivvd/
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374414/0/en/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change.

Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S. Food and Drug Administration for pre-exposure prophylaxis against COVID-19 in certain moderately to severely immunocompromised individuals for whom vaccination is not expected to provide adequate protection. Invivyd is also advancing additional antibody candidates for infectious disease indications.

The company was founded as Adagio Therapeutics and changed its name to Invivyd in 2023. Based in Waltham, Massachusetts, Invivyd conducts research and clinical development activities intended to support the availability of its antibody therapies in the United States and other markets. The company is led by Mark J. Esser, Ph.D., who serves as president and chief executive officer.

View Invivyd Profile
Earnings Tools